Canaccord Genuity Reiterates Buy Rating on Stoke Therapeutics, Inc. (STOK)
Rating Change Canaccord Genuity analysts reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) on August 04, 2026. Market Context Stoke Therapeutics, Inc.
Read more
